Antibody-drug Conjugates (ADC)

Fmoc-D-Val-Cit-PAB is a cleavable linker designed for antibody-drug conjugation (ADC). This compound facilitates the selective attachment of cytotoxic agents to antibodies, enhancing targeted delivery to diseased cells. Its unique cleavage properties enable the release of the active agent within the target tissue, making it a valuable tool in cancer therapeutics research and development.

Aminooxy-PEG2-BCN is a cleavable linker designed for use in antibody-drug conjugate (ADC) synthesis. This reagent features a BCN (cyclooctyne) moiety that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. Its unique structure enables efficient conjugation in the development of targeted therapeutics, enhancing both delivery and efficacy of payloads in cancer research and other biomedical applications.

Mal-bis-PEG3-DBCO is a cleavable linker designed for antibody-drug conjugate (ADC) synthesis, functioning through the efficient coupling of DBCO and azide moieties. This reagent incorporates a 3-unit polyethylene glycol (PEG) chain, enhancing solubility and biocompatibility. Its mechanism relies on strain-promoted alkyne-azide cycloaddition (SPAAC), making it ideal for precise conjugation applications in targeted drug delivery and cancer therapeutics research.

4-N3Pfp-NHS ester is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs), targeting the conjugation of therapeutic agents to antibodies. This compound features an azide group, enabling click chemistry through copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, as well as strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN groups. Its robust reactivity makes it an essential tool for enhancing the efficacy and selectivity of ADCs in cancer research and therapeutic development.

PC Alkyne-PEG4-NHS ester is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). Functioning as a PROTAC linker, this reagent features an alkyne group and participates in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions. Its unique structure enhances the specificity and efficiency of conjugating azide-containing molecules, making it valuable for various chemical biology applications, including targeted drug delivery and proteolysis targeting chimera (PROTAC) development.

Acid-PEG2-SS-PEG2-acid is a cleavable polyethylene glycol (PEG) linker designed for use in antibody-drug conjugates (ADCs). This four-unit PEG-based linker facilitates the conjugation of drugs to antibodies, enhancing delivery while maintaining therapeutic efficacy. Its disulfide bond allows for selective cleavage in reducing environments, making it suitable for targeted drug release in various biological applications, including cancer therapies.

Fmoc-D-Val-D-Cit-PAB is a cleavable linker specifically designed for antibody-drug conjugation (ADC). This reagent facilitates the attachment of therapeutic agents to antibodies, enhancing targeted delivery to cancer cells. Its biocompatibility and stability make it ideal for research applications in the development of novel ADCs for improved cancer therapy.

Sulfo-SPP sodium is a heterobifunctional crosslinker that serves as an antibody-drug conjugate (ADC) linker. It features thiol-cleavable properties, enabling selective release of therapeutics in targeted cells. This membrane-impermeable linker is suitable for use in various applications, including the design and development of ADCs for targeted cancer therapies.

MC-Val-D-Cit-PAB-PNP is a cleavable peptide linker designed for use in antibody-drug conjugates (ADCs). This linkage incorporates a maleimidocaproyl (Mc) group for efficient conjugation to antibodies, paired with a p-nitrophenol (PNP) moiety that facilitates attachment to antitumor agents. Its applications include enhancing targeted delivery of therapeutics and improving efficacy in cancer treatment research.

TCO-PEG4-DBCO is a versatile PROTAC linker known for its ability to facilitate the synthesis of proteolysis-targeting chimeras (PROTACs). This compound features a DBCO moiety that enables strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing compounds, while the TCO component allows for inverse electron demand Diels-Alder (iEDDA) reactions with tetrazine derivatives. TCO-PEG4-DBCO finds applications in the development of antibody-drug conjugates (ADCs), enhancing the precision and efficacy of targeted therapeutics. Its unique chemical properties make it a valuable tool for researchers in chemical biology and drug development.

Propargyl-PEG8-bromide is a PEG-based linker designed for use in antibody-drug conjugates (ADCs) and PROTAC synthesis. This non-cleavable linker includes an alkyne group, enabling its application in click chemistry through copper-catalyzed azide-alkyne cycloaddition (CuAAc). Its versatility makes it a valuable tool for researchers in the development of targeted therapeutics and for probing protein degradation mechanisms.

2,4-Diisopropylphenol is an important ADC linker that facilitates the conjugation of antibody-drug complexes. Its primary mechanism involves the formation of stable linkages between antibodies and cytotoxic agents, enhancing the therapeutic efficacy of targeted drug delivery systems. This compound is widely utilized in the development of antibody-drug conjugates (ADCs) for cancer therapeutics, allowing for precise targeting of tumor cells while minimizing off-target effects.

SPDV is a cleavable antibody-drug conjugate (ADC) linker designed to facilitate targeted delivery of therapeutics to cancer cells. Its primary mechanism involves selective cleavage in the presence of specific biological conditions, allowing for the release of cytotoxic agents directly within malignant tissues. SPDV is particularly useful in research applications focused on improving the efficacy of ADCs for the diagnosis and treatment of cancer and B cell proliferative diseases.

m-C-tri(CH2-PEG1-NHS ester) is a non-cleavable linker designed for use in antibody-drug conjugates (ADCs). This reagent facilitates the conjugation of antibodies to therapeutic agents, enhancing their delivery and efficacy while ensuring stability in circulation. Its application in ADC development supports targeted therapy research, particularly in cancer treatment and precision medicine.

m-PEG10-acid is a polyethylene glycol (PEG) linker designed for use in the synthesis of antibody-drug conjugates (ADCs) and PROTACs (Proteolysis Targeting Chimeras). This non-cleavable 10-unit PEG linker enhances solubility and stability, facilitating effective delivery of therapeutic agents to targeted cells. The compound is instrumental in chemical biology applications, aiding in the development of novel targeted therapies and research into protein degradation mechanisms.

N-Di(D-mannose)-PEG12-MC-VC-PAB-MMAE is an ADC linker designed for targeted cancer therapy. This compound facilitates the conjugation of cytotoxic agents to antibodies, enhancing selectivity and efficacy in tumor cells. Its utilization in antibody-drug conjugates provides a valuable tool for researchers investigating cancer treatments and mechanisms in various preclinical studies.

m-PEG5-succinimidyl carbonate is a non-cleavable linker designed for use in antibody-drug conjugates (ADCs). This 5-unit polyethylene glycol (PEG) linker facilitates the covalent attachment of drugs to antibodies, enhancing the therapeutic efficacy of ADCs. Additionally, m-PEG5-succinimidyl carbonate serves as a versatile component in the synthesis of PROTACs (proteolysis-targeting chimeras), aiding in targeted protein degradation research applications.

N-Bromoacetyl-β-alanine is a versatile PROTAC linker that functions through targeted protein degradation pathways. This compound facilitates the synthesis of PROTACs, enabling the development of novel therapeutic strategies. Additionally, N-Bromoacetyl-β-alanine serves as a cleavable linker for antibody-drug conjugates (ADCs), enhancing the delivery of cytotoxic agents to specific cancer cells. Its utility in these applications makes it a valuable tool in chemical biology research.

Me-Tet-PEG4-Maleimide is an ADC linker featuring four PEG units that facilitates drug conjugation through its tetrazine group. It engages in inverse electron demand Diels-Alder (iEDDA) reactions with trans-cyclooctene (TCO) compounds, enabling precise targeting in drug delivery applications. The maleimide moiety offers controlled reactivity, making it suitable for studies requiring stability in biological systems while maintaining effective linker performance in therapeutic contexts.

AcBut is a cleavable linker specifically designed for antibody-drug conjugates (ADCs), facilitating the synthesis of Ozogamicin. This linker promotes stable attachment while enabling release of the active drug upon reaching the target site, thereby enhancing therapeutic efficacy. It is invaluable in the development of ADCs aimed at precision cancer therapies, where targeted cell killing is essential.

Mal-GGG-Bal-NHS ester is an ADC linker that facilitates the conjugation of cytotoxic agents to antibodies, enabling the targeted delivery of drugs to cancer cells. This compound is instrumental in the development of antibody-drug conjugates (ADCs) for therapeutic applications, enhancing the efficacy and selectivity of cancer treatments. Its reactive NHS ester group ensures efficient linkage to amine-containing biomolecules, making it a valuable tool in pharmaceutical research and drug development.

Mal-amido-PEG1-C2-NHS ester is a non-cleavable antibody-drug conjugate (ADC) linker that features a maleimide functionality and an NHS ester. This compound is designed for the efficient labeling of primary amines (-NH2) present in proteins, amine-modified oligonucleotides, and other amine-containing molecules. Its versatility in conjugation applications makes it suitable for targeted drug delivery and therapeutic development in bioconjugation research.

SPDH is a cleavable linker specifically designed for antibody-drug conjugates (ADCs). It facilitates the selective release of therapeutic agents in targeted cancer therapies and B cell proliferative disorders. This compound enhances the efficacy of ADCs by ensuring the precise delivery of cytotoxic drugs to malignant cells, supporting advancements in targeted cancer treatment research.

Mal-PEG2-bis-PEG3-BCN is a cleavable linker designed for use in antibody-drug conjugates (ADCs). Featuring a BCN moiety, it facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, enhancing conjugation efficiency. This reagent is ideal for the development of targeted therapies in cancer research and other applications requiring precise drug delivery mechanisms.

TCO-SS-amine is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). Featuring a TCO group, this reagent facilitates the inverse electron demand Diels-Alder reaction (iEDDA) with tetrazine-containing molecules. Its selective and efficient coupling capabilities make TCO-SS-amine a valuable tool in ADC development, enabling targeted delivery of therapeutic agents in cancer research and drug discovery applications.

β-D-tetraacetylgalactopyranoside-PEG1-N3 serves as a cleavable linker in PROTAC (proteolysis-targeting chimera) research, facilitating the synthesis of antibody-drug conjugates (ADCs). This compound features an azide group that allows for click chemistry applications, including copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules. Additionally, it is capable of undergoing strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with partners containing DBCO or BCN moieties, making it a versatile tool for bioconjugation and targeted drug delivery studies.

Me-Tet-PEG4-COOH is an ADC linker featuring four polyethylene glycol (PEG) units, designed for effective conjugation in antibody-drug conjugate (ADC) applications. Its unique tetrazine group facilitates specific inverse electron demand Diels-Alder (iEDDA) reactions with trans-cyclooctene (TCO) derivatives, enabling precise and efficient targeting of therapeutic agents. This linker enhances the stability and solubility of ADCs, making it a valuable tool in cancer research and therapeutic development.

PPA is a specialized linker utilized in the formation of antibody-drug conjugates (ADCs), functioning primarily by facilitating the attachment of cytotoxic drugs to antibodies. This compound plays a crucial role in enhancing the therapeutic efficacy of ADCs by ensuring targeted delivery of the drug to cancer cells. PPA is essential for researchers developing novel ADCs aimed at improving treatment outcomes in oncology.

Bis-Tos-(2-hydroxyethyl disulfide) is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the selective release of therapeutic agents upon cellular uptake, enhancing the efficacy of targeted cancer therapies. Its bioactive properties make it suitable for various research applications in the development of ADCs, allowing for precise drug delivery and improved patient outcomes in oncology studies.

m-PEG8-MS is a polyethylene glycol (PEG)-based linker designed for use in antibody-drug conjugates (ADCs) and proteolysis-targeting chimeras (PROTACs). This cleavable linker facilitates the effective synthesis of ADCs, enhancing drug delivery specificity and potency. Its versatile applications in chemical biology allow for targeted degradation of selected proteins, making it a valuable tool in therapeutic development and research.

PDdEC-NB is a disulfide-cleavable linker designed for use in antibody-drug conjugates (ADCs). This reagent facilitates targeted drug delivery by enabling the selective release of cytotoxic agents in the presence of reducing conditions, thus enhancing therapeutic efficacy. It is suitable for applications in ADC development and optimization, contributing to improved specificity and reduced off-target effects in cancer therapeutics.

3,4-Dibromo-Mal-PEG4-Acid is a site-specific linker designed for antibody-drug conjugates (ADCs), featuring a dibromomaleimide moiety that enables dual substitution via its two bromine atoms. The carboxylic acid group can react with primary amines in the presence of coupling agents such as EDC and HATU, facilitating the formation of stable amide bonds. Additionally, the hydrophilic PEG4 linker enhances the solubility of the resulting conjugate in aqueous environments, making it suitable for various bioconjugation applications in chemical and biological research.

Boc-Gly-Gly-Gly-Gly-Gly is an antibody-drug conjugate (ADC) linker featuring a tert-butoxycarbonyl (Boc) protecting group on the N-terminus. The Boc group allows for selective deprotection under mild acidic conditions, yielding a free amine that can facilitate conjugation with various cytotoxic agents. This compound is instrumental in ADC development, enhancing the specificity and efficacy of targeted cancer therapies.

SNPB-sulfo-Me is a cleavable linker designed for the formulation of antibody-drug conjugates (ADCs). It facilitates the selective release of therapeutic agents upon internalization, enhancing the efficacy of targeted cancer therapies. This linker can be utilized in various research applications aimed at developing and optimizing ADCs for improved therapeutic outcomes.

NO2-SPP is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the effective attachment of cytotoxic agents to antibodies, ensuring precise delivery to target cells. Its utility in ADC development makes it a valuable tool for researchers in the fields of cancer therapeutics and bioconjugation technology.

Cbz-Phe-(Alloc)Lys-PAB-PNP is a cleavable linker designed for use in antibody-drug conjugates (ADCs). This compound facilitates the selective release of cytotoxic agents upon internalization by target cells, enhancing the therapeutic efficacy of ADCs. Its unique structure supports the effective conjugation of antibodies with drugs, making it suitable for applications in cancer research and targeted therapy development.

m-PEG6-SS-PEG6-methyl is a cleavable linker designed for use in antibody-drug conjugates (ADCs), consisting of a 12-unit polyethylene glycol (PEG) chain. This compound features a disulfide bond that enables controlled release of the drug payload in a reducing environment, enhancing the therapeutic efficacy of ADCs. It is ideal for research applications involving targeted cancer therapies and bioconjugation techniques.

Sulfo-SMPB sodium is a heterobifunctional ADC linker designed for covalent conjugation via its N-hydroxysuccinimide (NHS) ester and maleimide functional groups. This non-cleavable cross-linking reagent facilitates the attachment of amine- and sulfhydryl-containing biomolecules, making it valuable in the development of antibody-drug conjugates (ADCs) and other bioconjugation applications. Its properties enable precise targeting and enhance the stability of conjugated products in biological systems.

Propargyl-PEG1-SS-PEG1-C2-Boc is a versatile alkyl/ether-based linker with applications in PROTAC and antibody-drug conjugate (ADC) synthesis. This cleavable linker features an alkyne group, enabling its use in click chemistry via copper-catalyzed azide-alkyne cycloaddition (CuAAc). Propargyl-PEG1-SS-PEG1-C2-Boc is instrumental in the development of targeted therapeutic strategies, making it valuable for researchers in drug design and bioconjugation studies.

5-Maleimidovaleric acid is a cleavable linker specifically designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the stable attachment of drugs to antibodies while allowing for selective release of the therapeutic agent in targeted cells. Its application is critical in the development of advanced ADCs for targeted cancer therapy, enhancing therapeutic efficacy and reducing off-target effects.

MC-GGFG-NH-CH2-O-propionic acid is an antibody-drug conjugate (ADC) linker that facilitates the targeted delivery of therapeutic agents. This reagent plays a crucial role in the synthesis of ADCs, enhancing the effectiveness of cancer treatments by linking cytotoxic drugs to antibodies. Its applications extend to the development of novel bioconjugates for precise tumor targeting in research settings.

Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB is a cleavable three-unit polyethylene glycol (PEG) linker designed for the synthesis of antibody-drug conjugates (ADCs). This linker enhances the solubility and stability of the conjugate while facilitating targeted delivery of cytotoxic agents. It is suitable for research applications focused on developing ADCs for therapeutic use in oncology and other diseases.

Boc-VC-PAB-MMAF is a cleavable linker designed for the construction of antibody-drug conjugates (ADCs). This compound facilitates targeted delivery of cytotoxic agents to tumor cells, providing insights into the efficacy and mechanisms of cancer treatment. It is particularly useful in cancer research, enabling the development of innovative therapeutic strategies that enhance selective tumor targeting while minimizing systemic toxicity.

Tr-PEG8-OH is a non-cleavable linker composed of an 8 unit polyethylene glycol (PEG) chain, primarily utilized in the synthesis of PROTACs (proteolysis-targeting chimeras) and antibody-drug conjugates (ADCs). This PEG-based linker facilitates the development of optimized bioconjugates, enhancing their pharmacokinetic profiles and therapeutic efficacy. Tr-PEG8-OH is particularly valuable for research applications focusing on targeted protein degradation and drug delivery systems.

NH2-PEG4-GGFG-NH-CH2-O-CH2COOH is an amino-functionalized polyethylene glycol (PEG) linker designed for Antibody-Drug Conjugate (ADC) synthesis. This compound facilitates the formation of stable covalent bonds between antibodies and cytotoxic agents, enhancing targeted delivery and therapeutic efficacy. It is essential for research applications focused on developing and optimizing ADCs for cancer treatment and other diseases.

Sulfo-DMAC-SPP is a cleavable linker specifically designed for the construction of antibody-drug conjugates (ADCs). This reagent facilitates the selective attachment of cytotoxic agents to antibodies, thereby enhancing targeted delivery and efficacy in cancer therapy. Its incorporation into ADCs can improve therapeutic profiles by allowing controlled release of the drug within the tumor microenvironment, making it valuable for advancing research in targeted cancer treatments.

NH2-PEG4-GGFG-CH2-O-CH2-Cbz is a versatile linker specifically designed for the synthesis of Antibody-Drug Conjugates (ADCs). This compound facilitates efficient attachment of cytotoxic agents to antibodies, enabling targeted delivery for cancer therapy. Its unique structure promotes stability and optimal release profiles, making it suitable for research applications in drug development and formulation studies.

Propargyl-PEG4-thiol is a PEG-based linker specifically designed for use in the synthesis of PROTACs and non-cleavable antibody-drug conjugates (ADCs). This compound features an alkyne functional group that participates in copper-catalyzed azide-alkyne cycloaddition (CuAAc), facilitating precise conjugation with azide-containing molecules. Propargyl-PEG4-thiol is essential for advancing research in targeted protein degradation and therapeutic antibody development.

THP-PEG6-OH is a PEG-based linker designed for use in the synthesis of PROTACs (proteolysis-targeting chimeras) and non-cleavable antibody-drug conjugates (ADCs). This versatile linker, consisting of three ethylene glycol units, facilitates the conjugation of small molecules to targeting ligands. THP-PEG6-OH enables effective modulation of protein degradation pathways and enhances the therapeutic potential of ADCs in various biological research applications.

Mal-Sulfo-DBCO is a cleavable linker designed for use in antibody-drug conjugate (ADC) synthesis. Featuring a DBCO moiety, it facilitates the efficient strain-promoted alkyne-azide cycloaddition (SPAAC) reaction with azide-containing compounds. This property makes Mal-Sulfo-DBCO valuable for precise conjugation in targeted drug delivery applications, enhancing therapeutic efficacy while minimizing off-target effects.